US drug giant Amgen opens first next-gen facility in Tuas
Add BT as a preferred source
Singapore
AMERICAN drug-maker Amgen expects to roll out its products for treating osteoporosis and bone cancers from its new plant in Tuas by the end of 2016. The S$200 million plant in Tuas Biomedical Park is the first next-generation biomanufacturing facility in the world, and is the company's first investment in Singapore and in Asia.
A model of efficiency, it is cheaper to build and run than conventional facilities; it took only a quarter of the capital cost to construct, and will need only a third of the operating expenses of a conventional facility. And 15 months was all it took for it to be built - half the time it takes to build a traditional plant.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Strengthening Asean’s economic resilience through RCEP’s 2027 review
How China’s young workers are securing their future even as AI disrupts job market, triggers pay cuts
US-China rivalry and the Kindleberger Trap: Why inaction – not escalation – is the biggest risk
